DOCSLIB.ORG

Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Oncogene (2010) 29, 2013–2023 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc ORIGINAL ARTICLE Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets N Turner1, MB Lambros1, HM Horlings2,3, A Pearson1, R Sharpe1, R Natrajan1, FC Geyer1, M van Kouwenhove2, B Kreike4, A Mackay1, A Ashworth1, MJ van de Vijver2,3 and JS Reis-Filho1 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK; 2Department of Pathology, Academic Medical Center, Meibergdreef, Amsterdam, The Netherlands; 3Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands and 4Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands Triple negative breast cancers (TNBCs) have a relatively Introduction poor prognosis and cannot be effectively treated with current targeted therapies. We searched for genes that The identification of distinct subgroups of breast cancer have the potential to be therapeutic targets by identifying has led to the development of therapeutic strategies that genes consistently overexpressed when amplified. Fifty-six exploit the underlying biology of the subtype, with TNBCs were subjected to high-resolution microarray- hormonal therapies and HER2-targeting agents for based comparative genomic hybridization (aCGH), of hormone receptor-positive and HER2-positive breast which 24 were subjected to genome-wide gene expression cancers, respectively (Reis-Filho and Tutt, 2008; Schnei- analysis. TNBCs were genetically heterogeneous; no der et al., 2008). Tumours lacking expression of individual focal amplification was present at high freq- hormone receptors (oestrogen receptor (ER) and pro- uency, although 78.6% of TNBCs harboured at least one gesterone receptor (PR)) and HER2 (triple negative focal amplification. Integration of aCGH and expression breast cancers, TNBCs), on the other hand, pose a data revealed 40 genes significantly overexpressed when significant clinical challenge due to a poor under- amplified, including the known oncogenes and potential standing of the genetic alternations that underlie the therapeutic targets, FGFR2 (10q26.3), BUB3 (10q26.3), development of TNBC (Reis-Filho and Tutt, 2008; RAB20 (13q34), PKN1 (19p13.12) and NOTCH3 Schneider et al., 2008) and this is reflected in a lack of (19p13.12). We identified two TNBC cell lines with subtype-specific targeted therapies. FGFR2 amplification, which both had constitutive activa- TNBCs comprise a heterogeneous group of breast tion of FGFR2. Amplified cell lines were highly sensitive cancers and account for 10–15% (Agrawal et al., 2007; to FGFR inhibitor PD173074, and to RNAi silencing of Carey et al., 2007; Dent et al., 2007; Reis-Filho and FGFR2. Treatment with PD173074 induced apoptosis Tutt, 2008; Schneider et al., 2008) of all invasive breast resulting partly from inhibition of PI3K-AKT signalling. cancers. Histologically, the majority of TNBCs are Independent validation using publicly available aCGH grade III invasive ductal carcinomas of no special type, data sets revealed FGFR2 gene was amplified in 4% although the majority of medullary, metaplastic and (6/165) of TNBC, but not in other subtypes (0/214, adenoid cystic carcinomas also display a triple negative P ¼ 0.0065). Our analysis demonstrates that TNBCs are phenotype (Reis-Filho and Tutt, 2008). These tumours heterogeneous tumours with amplifications of FGFR2 in a are more prevalent in young women (o50 years) and in subgroup of tumours. women of African and Hispanic descent. TNBCs have a Oncogene (2010) 29, 2013–2023; doi:10.1038/onc.2009.489; poor prognosis characterized by early relapse (Tischko- published online 18 January 2010 witz and Foulkes, 2006; Dent et al., 2009), potentially reflecting the high proliferative rate of TNBCs. Simi- Keywords: triple negative breast cancer; microarrays; larly, women with TNBCs have a significantly shorter gene expression; comparative genomic hybridization; survival following recurrence when compared with those FGFR2 with non-triple negative cancers (Harris et al., 2006; Dent et al., 2007). Therefore, the identification of novel therapeutic targets for TNBCs is important if the outcome of patients with these tumours is to be improved. On the basis of the concept of oncogene addiction, we Correspondence: Dr N Turner, or Dr JS Reis-Filho, The Break- and others have demonstrated that genes that are through Breast Cancer Research Centre, Institute of Cancer Research, consistently overexpressed when amplified may be 237 Fulham Road, London, SW3 6JB, UK. E-mails: [email protected] or jorge.reis-fi[email protected] selectively required for the survival of cancer cells Received 18 August 2009; revised 30 November 2009; accepted 7 harbouring their amplification, and can be exploited as December 2009; published online 18 January 2010 potential therapeutic targets (Reis-Filho et al., 2006; Integrative molecular profiling of TNBC N Turner et al 2014 Bernard-Pierrot et al., 2008; Natrajan et al., 2009a). et al., 2009b). This analysis revealed that the expression Earlier studies have examined TNBCs with expression of 4972 out of 24 565 genes (20.2%) correlated with copy profiling (Kreike et al., 2007; Bertucci et al., 2008) and number changes (Pearson’s correlation adjusted microarray-based comparative genomic hybridization Po0.05, Supplementary Table 6). This analysis suggests (aCGH) (Han et al., 2008; Andre et al., 2009). These that a large proportion of the genes expressed in TNBCs studies have found TNBCs to be heterogeneous, with are at least in part regulated by copy number changes. complex genomic profiles and infrequent amplifications. Within this list, we determined the genes whose To identify amplicon drivers and genes that have the expression was significantly upregulated or downregu- potential to be therapeutic targets in TNBCs, we lated in the presence of copy number gain or loss, integrated aCGH and gene expression data from a large respectively (Mann–Whitney U adjusted Po0.05, Sup- series of TNBCs. Our aims were to characterize the plementary Table 7). We identified 324 genes whose genomic and transcriptomic profiles of TNBCs and mRNA expression levels were significantly higher in identify and validate genes that are recurrently amplified tumours harbouring DNA copy number gains and 39 and consistently overexpressed when amplified in genes whose mRNA expression levels were significantly TNBCs. We found more frequent high level, focal lower in tumours displaying DNA copy number loss. amplifications than described earlier (Chin et al., 2006), The lower number of genes downregulated when lost and identified potential therapeutic targets that are may stem from the slightly lower sensitivity of array consistently overexpressed when amplified. We vali- CGH to detect loss of a single copy of a genomic region dated the fibroblast growth factor receptor 2 (FGFR2) in highly aneuploid tumours (Ng et al., 2006), coupled gene as one of these targets and provided functional with the limitations of expression arrays to accurately data to suggest that this tyrosine kinase receptor may be determine the expression of genes expressed at low a novel therapeutic target in a subset of TNBCs levels. harbouring FGFR2 gene amplification. Ingenuity pathway analysis (IPA) of genes expressed at higher levels when gained revealed that 5 networks and 27 canonical pathways were significantly enriched (Supplementary Table 8), and only one network/ Results canonical pathway from genes expressed at lower levels when lost (Supplementary Table 9). Importantly, the TNBCs display complex genomic profiles canonical pathways of growth factors that have been We established the genomic array CGH profiles of 56 shown to have a function in breast cancer development TNBCs with an array CGH platform with an earlier and progression, or to be potential therapeutic targets, validated effective resolution of 50 kb. This revealed a were significantly enriched with genes upregulated when high level of genetic instability, with gain or loss gained (Table 1). Copy number gains of the tyrosine affecting a median of 44.4% of the genome (range kinase receptors were rare, and the growth factor 9.3–76.7%). Using the genomic pattern classification pathway enrichment reflected frequent copy number proposed by Hicks et al. (2006), 15 of the TNBCs (27%) gains and overexpression of key adapter molecules and were classified as ‘simplex’ and 41 (73%) were con- downstream signal transduction kinases (Table 1). The sidered to have ‘complex’ genomic patterns, of which 28 p53 signalling pathway was enriched for genes that are (50%) were ‘sawtooth’ and 13 (23%) were ‘firestorm’ upregulated when gained, including survivin (BIRC5). (Hicks et al., 2006). Given that the majority of TNBCs displayed ‘sawtooth’ patterns, it is not surprising that multiple regions of recurrent gains and losses were Recurrent amplified regions and potential amplicon identified (Figure 1a; Supplementary Table 4). In drivers agreement with earlier studies (Han et al., 2008; Andre We next analysed the data to identify the genes that were et al., 2009), loss of 1p36-p34, 5q11-q35, 8p23.3-p12 and significantly overexpressed when amplified in TNBCs, 17p13-q21 and gain of 3q22-q26, 6p25-p21, 7q32-q36, compared with non-amplified cancers (Figure 2). This 8p11-q24, 10p15.3-p11.21 and 12p13-p11 were found in analysis revealed only 40 genes (Mann–Whitney U-test 430% of TNBCs
Load more

Recommended publications
  • Analysis of Gene Expression Data for Gene Ontology
    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
    [Show full text]
  • The Utility of Genetic Risk Scores in Predicting the Onset of Stroke March 2021 6
    DOT/FAA/AM-21/24 Office of Aerospace Medicine Washington, DC 20591 The Utility of Genetic Risk Scores in Predicting the Onset of Stroke Diana Judith Monroy Rios, M.D1 and Scott J. Nicholson, Ph.D.2 1. KR 30 # 45-03 University Campus, Building 471, 5th Floor, Office 510 Bogotá D.C. Colombia 2. FAA Civil Aerospace Medical Institute, 6500 S. MacArthur Blvd Rm. 354, Oklahoma City, OK 73125 March 2021 NOTICE This document is disseminated under the sponsorship of the U.S. Department of Transportation in the interest of information exchange. The United States Government assumes no liability for the contents thereof. _________________ This publication and all Office of Aerospace Medicine technical reports are available in full-text from the Civil Aerospace Medical Institute’s publications Web site: (www.faa.gov/go/oamtechreports) Technical Report Documentation Page 1. Report No. 2. Government Accession No. 3. Recipient's Catalog No. DOT/FAA/AM-21/24 4. Title and Subtitle 5. Report Date March 2021 The Utility of Genetic Risk Scores in Predicting the Onset of Stroke 6. Performing Organization Code 7. Author(s) 8. Performing Organization Report No. Diana Judith Monroy Rios M.D1, and Scott J. Nicholson, Ph.D.2 9. Performing Organization Name and Address 10. Work Unit No. (TRAIS) 1 KR 30 # 45-03 University Campus, Building 471, 5th Floor, Office 510, Bogotá D.C. Colombia 11. Contract or Grant No. 2 FAA Civil Aerospace Medical Institute, 6500 S. MacArthur Blvd Rm. 354, Oklahoma City, OK 73125 12. Sponsoring Agency name and Address 13. Type of Report and Period Covered Office of Aerospace Medicine Federal Aviation Administration 800 Independence Ave., S.W.
    [Show full text]
  • Subcellular Localization and Mitotic Interactome Analyses Identify SIRT4 As a Centrosomally Localized and Microtubule Associated Protein
    cells Article Subcellular Localization and Mitotic Interactome Analyses Identify SIRT4 as a Centrosomally Localized and Microtubule Associated Protein 1 1, 1 1 Laura Bergmann , Alexander Lang y , Christoph Bross , Simone Altinoluk-Hambüchen , Iris Fey 1, Nina Overbeck 2, Anja Stefanski 2, Constanze Wiek 3, Andreas Kefalas 1, Patrick Verhülsdonk 1, Christian Mielke 4, Dennis Sohn 5, Kai Stühler 2,6, Helmut Hanenberg 3,7, Reiner U. Jänicke 5, Jürgen Scheller 1, Andreas S. Reichert 8 , Mohammad Reza Ahmadian 1 and Roland P. Piekorz 1,* 1 Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; [email protected] (L.B.); [email protected] (A.L.); [email protected] (C.B.); [email protected] (S.A.-H.); [email protected] (I.F.); [email protected] (A.K.); [email protected] (P.V.); [email protected] (J.S.); [email protected] (M.R.A.) 2 Molecular Proteomics Laboratory, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; [email protected] (N.O.); [email protected] (A.S.); [email protected] (K.S.) 3 Department of Otolaryngology and Head/Neck Surgery, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; [email protected] (C.W.); [email protected] (H.H.) 4 Institute of Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; [email protected]
    [Show full text]
  • Iii COMPUTATIONAL APPROACHES for ASSESSING KINOME
    COMPUTATIONAL APPROACHES FOR ASSESSING KINOME FUNCTION AND DEREGULATION A Dissertation Presented to the Faculty of the Weill Cornell Graduate School of Medical Sciences in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Charles Joseph Murphy August 2018 iii © 2018 Charles Joseph Murphy ALL RIGHTS RESERVED COMPUTATIONAL APPROACHES FOR ASSESSING KINOME FUNCTION AND DEREGULATION Charles Joseph Murphy, PhD Cornell University 2018 Protein kinases are a diverse family of about 500 proteins that all share the common ability to catalyze phosphorylation of the side chains of amino acids in proteins. Kinases play a vital role across diverse biological functions including proliferation, differentiation, cell migration, and cell-cycle control. Moreover, they are frequently altered across most cancers types and have been a focus for development of anti- cancer drugs, which has led to the development of 38 approved kinase inhibitors as of 2018. In this thesis, I developed two orthogonal computational approaches for investigating kinase function and deregulation. Starting with data from a large cohort of mouse triple negative breast cancer (TNBC) tumors, I use a combination of whole exome sequencing (WES) and RNA-seq to identify somatic alterations that drive individual tumors. I discovered that a large number of these alterations involve protein kinases and subsequent therapeutic targeting led to tumor regression. For my second approach, I utilized a large peptide library dataset from about 300 kinases. Which kinase phosphorylate which phosphorylation site is determined by both kinase- intrinsic and contextual factors. Peptide library approaches provide kinase-intrinsic amino acid specificity, which I used to predict novel kinase substrates and map out kinase phosphorylation networks.
    [Show full text]
  • Genome-Wide Analysis of Transcriptional Bursting-Induced Noise in Mammalian Cells
    bioRxiv preprint doi: https://doi.org/10.1101/736207; this version posted August 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Genome-wide analysis of transcriptional bursting-induced noise in mammalian cells Authors: Hiroshi Ochiai1*, Tetsutaro Hayashi2, Mana Umeda2, Mika Yoshimura2, Akihito Harada3, Yukiko Shimizu4, Kenta Nakano4, Noriko Saitoh5, Hiroshi Kimura6, Zhe Liu7, Takashi Yamamoto1, Tadashi Okamura4,8, Yasuyuki Ohkawa3, Itoshi Nikaido2,9* Affiliations: 1Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Hiroshima, 739-0046, Japan 2Laboratory for Bioinformatics Research, RIKEN BDR, Wako, Saitama, 351-0198, Japan 3Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka, 812-0054, Japan 4Department of Animal Medicine, National Center for Global Health and Medicine (NCGM), Tokyo, 812-0054, Japan 5Division of Cancer Biology, The Cancer Institute of JFCR, Tokyo, 135-8550, Japan 6Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa, 226-8503, Japan 7Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, 20147, USA 8Section of Animal Models, Department of Infectious Diseases, National Center for Global Health and Medicine (NCGM), Tokyo, 812-0054, Japan 9Bioinformatics Course, Master’s/Doctoral Program in Life Science Innovation (T-LSI), School of Integrative and Global Majors (SIGMA), University of Tsukuba, Wako, 351-0198, Japan *Corresponding authors Corresponding authors e-mail addresses Hiroshi Ochiai, [email protected] Itoshi Nikaido, [email protected] bioRxiv preprint doi: https://doi.org/10.1101/736207; this version posted August 15, 2019.
    [Show full text]
  • Sirt1 Is Regulated by Mir-135A and Involved in DNA Damage Repair During Mouse Cellular Reprogramming
    www.aging-us.com AGING 2020, Vol. 12, No. 8 Research Paper Sirt1 is regulated by miR-135a and involved in DNA damage repair during mouse cellular reprogramming Andy Chun Hang Chen1,2,*, Qian Peng2,*, Sze Wan Fong1, William Shu Biu Yeung1,2, Yin Lau Lee1,2 1Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong SAR, China 2Shenzhen Key Laboratory of Fertility Regulation, The University of Hong Kong Shenzhen Hospital, Shenzhen, China *Co-first authors Correspondence to: Yin Lau Lee, William Shu Biu Yeung; email: [email protected], [email protected] Keywords: mouse induced pluripotent stem cells, cellular reprogramming, Sirt1, miR-135a, DNA damage repair Received: December 30, 2019 Accepted: March 30, 2020 Published: April 26, 2020 Copyright: Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Sirt1 facilitates the reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs). It is regulated by micro-RNA and reported to be a target of miR-135a. However, their relationship and roles on cellular reprogramming remain unknown. In this study, we found negative correlations between miR-135a and Sirt1 during mouse embryonic stem cells differentiation and mouse embryonic fibroblasts reprogramming. We further found that the reprogramming efficiency was reduced by the overexpression of miR-135a precursor but induced by the miR-135a inhibitor. Co-immunoprecipitation followed by mass spectrometry identified 21 SIRT1 interacting proteins including KU70 and WRN, which were highly enriched for DNA damage repair.
    [Show full text]
  • Genetic Variant in 3' Untranslated Region of the Mouse Pycard Gene
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.26.437184; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 2 3 Title: 4 Genetic Variant in 3’ Untranslated Region of the Mouse Pycard Gene Regulates Inflammasome 5 Activity 6 Running Title: 7 3’UTR SNP in Pycard regulates inflammasome activity 8 Authors: 9 Brian Ritchey1*, Qimin Hai1*, Juying Han1, John Barnard2, Jonathan D. Smith1,3 10 1Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, 11 Cleveland, OH 44195 12 2Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 13 44195 14 3Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western 15 Reserve University, Cleveland, OH 44195 16 *, These authors contributed equally to this study. 17 Address correspondence to Jonathan D. Smith: email [email protected]; ORCID ID 0000-0002-0415-386X; 18 mailing address: Cleveland Clinic, Box NC-10, 9500 Euclid Avenue, Cleveland, OH 44195, USA. 19 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.26.437184; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 20 Abstract 21 Quantitative trait locus mapping for interleukin-1 release after inflammasome priming and activation 22 was performed on bone marrow-derived macrophages (BMDM) from an AKRxDBA/2 strain intercross.
    [Show full text]
  • UNIVERSITY of CALIFORNIA RIVERSIDE Investigations Into The
    UNIVERSITY OF CALIFORNIA RIVERSIDE Investigations into the Role of TAF1-mediated Phosphorylation in Gene Regulation A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Cell, Molecular and Developmental Biology by Brian James Gadd December 2012 Dissertation Committee: Dr. Xuan Liu, Chairperson Dr. Frank Sauer Dr. Frances M. Sladek Copyright by Brian James Gadd 2012 The Dissertation of Brian James Gadd is approved Committee Chairperson University of California, Riverside Acknowledgments I am thankful to Dr. Liu for her patience and support over the last eight years. I am deeply indebted to my committee members, Dr. Frank Sauer and Dr. Frances Sladek for the insightful comments on my research and this dissertation. Thanks goes out to CMDB, especially Dr. Bachant, Dr. Springer and Kathy Redd for their support. Thanks to all the members of the Liu lab both past and present. A very special thanks to the members of the Sauer lab, including Silvia, Stephane, David, Matt, Stephen, Ninuo, Toby, Josh, Alice, Alex and Flora. You have made all the years here fly by and made them so enjoyable. From the Sladek lab I want to thank Eugene, John, Linh and Karthi. Special thanks go out to all the friends I’ve made over the years here. Chris, Amber, Stephane and David, thank you so much for feeding me, encouraging me and keeping me sane. Thanks to the brothers for all your encouragement and prayers. To any I haven’t mentioned by name, I promise I haven’t forgotten all you’ve done for me during my graduate years.
    [Show full text]
  • Cases. Genes Are Rank-Ordered According to Their P-Value
    Table 1. Genes differentially expressed between adult T-ALL overexpressing ABL1 and the remaining T- ALL cases. Genes are rank-ordered according to their p-value. Probeset Gene symbol p-value FC GenBank Gene function Chromosome Expression in ID ID location “high” ABL1 cases 38847_at MELK <10-4 2.79 NM_014791 Protein amino acid phosphorylation 9p13.2 High 37999_at CPOX <10-4 2.86 NM_000097 Heme biosynthesis 3q12 High 38711_at CLASP2 <10-4 2.33 NM_015097 Cell division 3p23 High 40822_at NFATC3 0.00011 2.06 NM_004555 Regulation of transcription from 16q22.2 High RNA polymerase II promoter 41638_at PPWD1 0.00025 2.13 NM_015342 Protein folding 5q12.3 High 41278_at BAF53 0.00085 2.08 NM_004301 Regulation of transcription, 3q26.33 High DNA-dependent 39388_at CAMK2G 0.00088 2.32 NM_001222 Protein amino acid phosphorylation 10q22 High 32916_at PTPRE 0.0011 2.13 NM_006504 Protein amino acid dephosphorylation 10q26 High 36511_at SACM1L 0.0014 2.16 NM_014016 Unknown 3p21.3 High 38834_at TOPBP1 0.0015 2.55 NM_007027 DNA replication and 3q22.1 High chromosome cycle 33301_g_at CDC2L1 0.0017 2.16 NM_001787 Regulation of transcription, 1p36 High DNA-dependent 32767_at SIL 0.0025 2.23 NM_003035 Cell proliferation 1p32 High 40828_at ARHGEF7 0.0025 2.08 NM_003899 Signal transduction 13q34 High 38431_at MAPK9 0.0026 2.24 NM_002752 Protein amino acid phosphorylation 5q35 High 35663_at NPTX2 0.0028 3.68 NM_002523 Synaptic transmission 7q21.3-q22.1 High 38325_at MINPP1 0.003 2.58 NM_004897 Multiple inositol-polyphosphate 10q23 High phosphatase activity 35747_at
    [Show full text]
  • Anti-PLEKHA1 / TAPP1 Antibody (ARG42988)
    Product datasheet [email protected] ARG42988 Package: 100 μl anti-PLEKHA1 / TAPP1 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes PLEKHA1 / TAPP1 Tested Reactivity Hu, Ms, Rat Tested Application IP, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name PLEKHA1 / TAPP1 Antigen Species Human Immunogen Synthetic peptide of Human PLEKHA1 / TAPP1. Conjugation Un-conjugated Alternate Names Pleckstrin homology domain-containing family A member 1; TAPP1; Tandem PH domain-containing protein 1; TAPP-1; PH domain-containing family A member 1 Application Instructions Application table Application Dilution IP 1:20 WB 1:1000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control K562 Calculated Mw 46 kDa Observed Size ~ 46 kDa Properties Form Liquid Purification Affinity purified. Buffer 50 nM Tris-Glycine (pH 7.4), 0.15M NaCl, 0.01% Sodium azide, 40% Glycerol and 0.05% BSA. Preservative 0.01% Sodium azide Stabilizer 40% Glycerol and 0.05% BSA Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol PLEKHA1 Gene Full Name pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1 Background This gene encodes a pleckstrin homology domain-containing adapter protein.
    [Show full text]
  • Transcriptome Analysis of Human Diabetic Kidney Disease
    ORIGINAL ARTICLE Transcriptome Analysis of Human Diabetic Kidney Disease Karolina I. Woroniecka,1 Ae Seo Deok Park,1 Davoud Mohtat,2 David B. Thomas,3 James M. Pullman,4 and Katalin Susztak1,5 OBJECTIVE—Diabetic kidney disease (DKD) is the single cases, mild and then moderate mesangial expansion can be leading cause of kidney failure in the U.S., for which a cure has observed. In general, diabetic kidney disease (DKD) is not yet been found. The aim of our study was to provide an considered a nonimmune-mediated degenerative disease unbiased catalog of gene-expression changes in human diabetic of the glomerulus; however, it has long been noted that kidney biopsy samples. complement and immunoglobulins sometimes can be de- — tected in diseased glomeruli, although their role and sig- RESEARCH DESIGN AND METHODS Affymetrix expression fi arrays were used to identify differentially regulated transcripts in ni cance is not clear (4). 44 microdissected human kidney samples. The DKD samples were The understanding of DKD has been challenged by multi- significant for their racial diversity and decreased glomerular ple issues. First, the diagnosis of DKD usually is made using filtration rate (~20–30 mL/min). Stringent statistical analysis, using clinical criteria, and kidney biopsy often is not performed. the Benjamini-Hochberg corrected two-tailed t test, was used to According to current clinical practice, the development of identify differentially expressed transcripts in control and diseased albuminuria in patients with diabetes is sufficient to make the glomeruli and tubuli. Two different Web-based algorithms were fi diagnosis of DKD (5). We do not understand the correlation used to de ne differentially regulated pathways.
    [Show full text]
  • Structure and Mechanism of the RNA Polymerase II Transcription Machinery
    Downloaded from genesdev.cshlp.org on October 9, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Structure and mechanism of the RNA polymerase II transcription machinery Allison C. Schier and Dylan J. Taatjes Department of Biochemistry, University of Colorado, Boulder, Colorado 80303, USA RNA polymerase II (Pol II) transcribes all protein-coding ingly high resolution, which has rapidly advanced under- genes and many noncoding RNAs in eukaryotic genomes. standing of the molecular basis of Pol II transcription. Although Pol II is a complex, 12-subunit enzyme, it lacks Structural biology continues to transform our under- the ability to initiate transcription and cannot consistent- standing of complex biological processes because it allows ly transcribe through long DNA sequences. To execute visualization of proteins and protein complexes at or near these essential functions, an array of proteins and protein atomic-level resolution. Combined with mutagenesis and complexes interact with Pol II to regulate its activity. In functional assays, structural data can at once establish this review, we detail the structure and mechanism of how enzymes function, justify genetic links to human dis- over a dozen factors that govern Pol II initiation (e.g., ease, and drive drug discovery. In the past few decades, TFIID, TFIIH, and Mediator), pausing, and elongation workhorse techniques such as NMR and X-ray crystallog- (e.g., DSIF, NELF, PAF, and P-TEFb). The structural basis raphy have been complemented by cryoEM, cross-linking for Pol II transcription regulation has advanced rapidly mass spectrometry (CXMS), and other methods. Recent in the past decade, largely due to technological innova- improvements in data collection and imaging technolo- tions in cryoelectron microscopy.
    [Show full text]